Duke Street Bio is focused on developing innovative cancer therapies that leverage the vulnerabilities in DNA Damage Response (DDR) mechanisms and the immune system's capabilities. Their approach utilizes precision medicine to target specific genetic alterations in cancer, particularly through the development of highly selective inhibitors for the enzyme PARP1. These second-generation PARP1 inhibitors aim to enhance therapeutic efficacy while minimizing hematological toxicities associated with earlier, non-selective inhibitors. By specifically targeting PARP1, Duke Street Bio seeks to improve treatment outcomes for patients with tumors exhibiting homologous repair deficiencies, such as those with BRCA mutations.

In addition to their work on PARP1, Duke Street Bio is advancing next-generation immuno-oncology therapies. They are developing PARP7 inhibitors that aim to convert immune-resistant "cold" tumors into immune-responsive "hot" tumors by restoring Type I interferon signaling within the tumor microenvironment. This approach not only enhances the immune response against tumors but also synergizes with existing treatments like chemotherapy and radiotherapy, which induce DNA damage. By bridging the gap between DNA damage and immune activation, Duke Street Bio's therapies have the potential to significantly improve patient outcomes in oncology.

United Kingdom

Duke Street Bio is focused on exploiting tumour genetic vulnerabilities and harnessing the natural power of the body’s immune system to fight cancer.

Duke Street Bio

Company Details